| Literature DB >> 26258796 |
Martina Miotto1, Ricardo M Gouveia2, Che J Connon3.
Abstract
The increasing interest in effort towards creating alternative therapies have led to exciting break<span class="Chemical">throughs in the attempt to bio-fabricate and engineer live tissues. This has been particularly evident in the development of new approaches applied to reconstruct corneal tissue. The need for tissue-engineered corneas is largely a response to the shortage of <span class="Species">donor tissue and the lack of suitable alternative biological scaffolds preventing the treatment of millions of blind people worldwide. This review is focused on recent developments in corneal tissue engineering, specifically on the use of self-assembling peptide amphiphiles for this purpose. Recently, peptide amphiphiles have generated great interest as therapeutic molecules, both in vitro and in vivo. Here we introduce this rapidly developing field, and examine innovative applications of peptide amphiphiles to create natural bio-prosthetic corneal tissue in vitro. The advantages of peptide amphiphiles over other biomaterials, namely their wide range of functions and applications, versatility, and transferability are also discussed to better understand how these fascinating molecules can help solve current challenges in corneal regeneration.Entities:
Keywords: bioactive molecules; cornea; corneal diseases; corneal tissue engineering; peptide amphiphiles; tissue engineering; wound healing
Year: 2015 PMID: 26258796 PMCID: PMC4598678 DOI: 10.3390/jfb6030687
Source DB: PubMed Journal: J Funct Biomater ISSN: 2079-4983
Figure 1The human central cornea in cross-section. The outer-, anterior-most surface of the cornea comprises a non-keratinized, multi-layered epithelium (blue) supported by a basement membrane and above the Bowman’s layer (yellow). The middle stromal tissue comprises 90% of the cornea’s thickness, and is sparsely populated with keratocytes (green) interspersed within approximately 200 lamellae of dense, collagen- and proteoglycan-rich extracellular matrix (lines). The innermost posterior tissue consists of a single layer of endothelial cells (red) supported by the Descemet’s membrane (grey).
Figure 2Examples of supramolecular PA nanostructures. Graphical representation of some representative structures obtained by PAs self-assembly: (A) nanofibers; (B) micelles; and (C) multi-layered nanotapes. All three structures have a hydrophilic outer corona comprised of bioactive peptide (blue) and self-assembly-inducing/spacer sequence (white), and a hydrophobic inner core with organized and/or non-organized PA tails (red and green, respectively) (adapted from [63,79]).
Main works involving the use of peptide amphiphiles in regenerative medicine. The table reports the PA used, its chemical structure, the aim of the studies, the source of the bioactive sequence, the concentration of PA used, and its form.
| PA | Chemical Structure | Aim | Source | [PA] wt % | PA Form | Reference |
|---|---|---|---|---|---|---|
| C16-C4-G3-S-RGD | Bone regeneration | Fibronectin | 0.1 | coating | [ | |
| C12-HSNGLPLGGGS | Cartilage regeneration | 1 | hydrogel | [ | ||
| C16-V2A2E2-NH2 | Cavernous nerve regeneration | 0.85 | hydrogel | [ | ||
| C16-C4-G3- LRKKLGKA | Blood vessels regeneration | Heparin binding consensus sequence | 3 | hydrogel | [ | |
| C16-KTTKS | Skin regeneration | Procollagen I | 0.0003 | solution | [ |
Main works involving the use of peptide amphiphiles in corneal tissue engineering. The table reports the PA used, the source of the bioactive sequence, the PA biological effect, the concentration of PA used, and its form.
| PA | Source | Biological Effect | [PA] wt % | PA Form | Reference |
|---|---|---|---|---|---|
| C16-G3-RGD/RGDS + C16-ETTES | Fibronectin | Enhanced adhesion and proliferation of hCSFs | 1 to 0.005 | coating | [ |
| A6-RGDS | Fibronectin | Enhanced adhesion and proliferation of hCSFs | 1 to 0.1 | coating | [ |
| C16-TPGPQGIAGQ-RGDS | MMP cleavage sequence + Fibronectin | Promoted adhesion andgrowth of hCSFs. Stimulated collagen production. Governed tissues lift-up | 2 | coating | [ |
| Fmoc-RGDS | Fibronectin | Enhanced cell attachment, proliferation and viability | 1 | solution | [ |
| C16-KTTKS | Procollagen I | Stimulated collagen production from hCSFs | 0.002, 0.004, 0.008 | solution | [ |
| C12-VVAGKYIGSR | Laminin | Enhanced keratocyte proliferation and migration, and stimulated collagen I synthesis | 0.2 | coating | [ |
| C16-YEALRVANEVTLN | Lumican | Stimulated collagen I production | 0.01, 0.005, 0.0025 | solution | [ |
Figure 3Bio-fabrication and controlled self-release of live tissues using PA coating templates. Schematic representation of the method used for the in vitro bio-fabrication and lift-off of human corneal stromal tissues, previously reported in [74]. Cells isolated from human donors were seeded and grown on low-attachment plates previously coated with a PA carrying both the MMP1-sensitive sequence and the RGDS cell adhesion motive. Cells were cultured in serum-free medium containing retinoic acid (RA) for 90 days and accumulated large quantities of corneal-specific stromal extracellular matrix. Subsequently, the bio-fabricated tissues were induced to express MMPs due to RA removal from the medium. In three days, the tissues expressed enough endogenous MMPs into the culture supernatant to provide the cue to degrade the adhesive PA coating, and induce their own release. The resulting free-floating corneal stromal equivalents were scaffold-free, easy to handle, and retained their shape and structural integrity for more than 18 months in storage.
Figure 4Schematic representation of the effect of Fmoc-RGDS PA on collagen gel contraction under different culture conditions. Human corneal stromal fibroblasts were encapsulated within uncompressed collagen gels that have been functionalized with the fibril-forming Fmoc-RGDS PA (+fPA), or produced without it (CTR). The relative contraction of collagen gels after seven days in serum-free medium (SFM) was negligible, but significantly minimized by the presence of the structural PA in serum-containing media alone (+FBS) or supplemented with 50 µM of soluble PA (+sPA) or cyclic RGD peptide (+cRGD) (adapted from [43]).